cyrilzakka/clinical-trials huggingface dataset:
Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment

RATIONALE: Gathering information about survivors of prostate cancer and their partners may help doctors learn more about the goals for sexual functioning after cancer treatment. PURPOSE: This clinical trial is studying the goals of sexual functioning in prostate cancer survivors and their partners after cancer treatment.

Detailed DescriptionOBJECTIVES:

I. To collect data on the goals of sexual functioning among prostate cancer survivors and their partners following cancer treatment in order to identify specific components of interventions for future grant submissions on the psychosexual needs of prostate cancer survivors.

OUTLINE:

Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.

Eligibility Criteria:
Inclusion Criteria:

* Prostate cancer survivors who are: willing and able to provide informed consent; able to read, write, and speak English; married or are in married-like relationship; completed radiation or surgery for their prostate cancer 6 months to 5 years ago
* Partners of prostate cancer survivors must be: willing and able to provide informed consent; able to read, write, and speak English

Exclusion Criteria:

* Prostate cancer survivors will be excluded if they have undergone androgen deprivation therapy within the past 6 months and if their partners refuse to participate
Post-operative Drainage After Pancreaticoduodenectomy

The study compares regular use of surgical drains and no use of surgical drains in patients subjected to pancreaticoduodenectomy with expected low to intermediate risk for post operative pancreatic fistula.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing pancreaticoduodenectomy of both sexes
* Patients with predicted risk score of 10 or less of pancreatic fistula
* Written informed consent
* Expected survival time \> 6 months

Exclusion Criteria:

* Patients with predicted high risk of fistula with a risk score above 10
* Patients with intraabdominal abscess or infection
* ASA score \> 3
* Pregnancy
* Expected lack of compliance
Monitoring Devices in Prediction of Fluid Responsiveness in Severe Sepsis and Septic Shock

Comparison of noninvasive cardiac output monitor (NICOM, Cheetah Medical) with Edwards FloTrac minimally-invasive cardiac output monitor in predicting fluid responsiveness in sepsis and septic shock.

Study will evaluate ability of passive leg raise test to predict fluid responsiveness in patients in septic shock, on vasopressors, using both the NICOM and FloTrac devices. An increase in CI, SVI, or Pulse Pressure of \>10% in response to the passive leg raise will be considered a positive passive leg raise test, and the same indicators will be considered a significant response to a fluid challenge with either crystalloids or colloids.Each device will be evaluated independently, but simultaneously.

Eligibility Criteria:
Inclusion Criteria:

* All adult patients with severe sepsis or septic shock, who have arterial catheter placed with FloTrac monitor, with or without a central venous catheter.

Exclusion Criteria:

* Declination of consent
* Known allergy to adhesive
* Pregnancy
* Contraindication to raising legs or head to 45 degrees for 3 minute intervals
Virtual Reality Effect in Geriatric Individuals

This study aimed to determine the effect of a virtual reality experience on pain, depression and functional adequacy in geriatric individuals living in a nursing home.

A virtual reality video with dance moves has been applied to the experimental group participants. Each video takes 3 minutes, and the elderly person has been put into practice at least 30 minutes after having breakfast in 3-minute periods and at least 30 minutes after dinner. In the morning and evening, 15 minutes, 2 times a day, a total of 9 days were applied for 3 weeks. The application lasted a total of 3 weeks. Scales were applied 1 week after the virtual reality application was completed and 1 month after the experimental group. The scales were filled in the control group at the same time.

It is recommended that the future studies be conducted with larger samples on pain, depression, life quality and functionality.

Eligibility Criteria:
Inclusion Criteria:

* Suffering from musculoskeletal pain in the last 3 years,
* Being energetic (Being independent in the daily life activities),
* Being able to stand up without help before 30 seconds and walk at least six meters without help,
* Individuals with blood sugar ranging between 90-200 mg/dl prior to the application,
* Individuals with blood pressure ranging between 130-70 mm/Hg prior to the application,
* Not having neurological and psychiatric diseases,
* No history of fall,
* Being literate,
* Not being visually-hearing impaired,
* Being able to communicate verbally.

Exclusion Criteria:

* Pependent patients
* Patients with psychiatric illness
* Patients with joint pain disease diagnosis
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease

The investigators aimed to reveal the relationship between serum markers of pyroptosis, GVHD biomarkers and endothelial damage markers in patients who were planned for allogeneic stem cell transplantation for AML and developed GVHD during follow-up. Secondary outcomes of the study were to demonstrate the role of pyroptosis in the pathophysiology of GVHD and transplantation-associated endothelial injury using serum plasma samples; the efficacy of GVHD biomarkers used to demonstrate organ-specific involvement; and the efficacy of GVHD biomarkers and endothelial injury markers in predicting the development of GVHD, transplantation-associated endothelial injury and non-relapse mortality.

In the study, in patients who were planned to receive allogeneic stem cell transplantation for AML, pre-transplant period (before and after central catheter insertion) and post-transplant period (+1, +7, +14, +28, +60 and +100 days in the post-transplant period) serum pyroptosis markers (Serum Gasdermin-D and NLRP-3 Inflammasome levels), GVHD biomarkers (REG-3 alpha, ST2, ELAFIN, HGF, ILR2-alpha, CXCL 9, CXCL 10, CXCL11, BAFF, TNF-alpha, I IL8, IL6 , IL18 , I IL1-beta , IL12 , IFN-gamma) and endothelial damage markers (serums-ICAM , sE-selectin , sVCAM , ANG2 , CRP , vWF , Factor 8 , LDH , d-dimer , transaminase enzyme levels and before transplantation, The aim of this study was to determine the relationship between basic biomarkers in pyroptosis and biomarkers with high predictive value in GVHD and markers of endothelial damage in patients who develop GVHD during follow-up using nail bed capillaroscopic examination and fibroelastographic evaluation to be performed on the twenty-first and hundredth days after transplantation.The serum samples obtained will be compared with the groups of patients with and without GVHD at the planned 1-year follow-up.

Patients diagnosed with AML between 15.11.2023 and 15.11.2024 will be included in the study and a total of 2 years of clinical follow-up is planned.

In case of loss of participants during follow-up, the study planned to recruit new patients with AML who were scheduled for transplantation between November 15, 2023 and November 15, 2024.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Patients with acute myeloid leukemia undergoing allogeneic bone marrow transplantation
* Patients followed up by the Department of Hematology, Ankara University Faculty of Medicine Hospitals

Exclusion Criteria:

* Patients under 18 years of age
* Patients with non-AML transplant indication
* Patients not followed up by the Department of Hematology, Ankara University Faculty of Medicine Hospitals
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of ciclesonide MDI for the treatment of symptomatic COVID-19 infection. Enrolled patients were male and female adults and adolescents 12 years of age or older with confirmed COVID-19 infection who were currently exhibiting symptoms of the disease and who were not currently hospitalized or under immediate consideration for hospitalization at the time of enrollment. The study consisted of an initial screening/enrollment/randomization visit, a 30-day treatment period, and a follow-up period.

Eligibility Criteria:
Inclusion Criteria

Patients eligible for enrollment in the study must meet all the following criteria:

1. Male and female adults and adolescents (12 years of age and above).
2. Positive SARS-CoV-2 rapid molecular diagnostic test within 72 hours prior to enrollment.
3. Patient is not currently hospitalized or under immediate consideration for hospitalization at the time of enrollment.
4. Patient is currently experiencing symptoms of fever, cough, and/or dyspnea.
5. Patient has an oxygen saturation level greater than 93%.
6. Ability to show adequate use of MDI, including inhalation technique.
7. Patient, parent/legal guardian, or legally-authorized representative must have signed a written informed consent before administration of any study-specific procedures.

Exclusion Criteria

Patients meeting any of the following criteria are not eligible for participation in the study:

1. Existence of any life-threatening co-morbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion.
2. History of hypersensitivity to ciclesonide.
3. Treatment with inhaled or intranasal corticosteroids within 14 days of the screening/ enrollment/randomization visit.
4. Treatment with oral corticosteroids within 90 days of the screening/enrollment/randomization visit.
5. Participation in any other clinical trial or use of any investigational agent within 30 days of the screening/enrollment/randomization visit.
6. Currently receiving treatment with hydroxychloroquine/chloroquine.
7. Patients with cystic fibrosis.
8. Patients with idiopathic pulmonary fibrosis.
Prospective Randomized Comparison of Conservative and Opertaive Treatment of Radius Fractures in Elderly Patients

Elderly Patients often suffer from radius fracture. Treatment options are conservative and operative. Aim of the stdy is to find out if there are diffrences in Patient's satisfaction depending on the different treatment.

A randomized prospective trial is palnned

Patients of 70 years and more of age who suffer from C1 or C2 radius fracture are randomized treated by conservative treatment and operative treatment.

Primary aim is PRWE, secondary ROM as well as power and DASH score.

Eligibility Criteria:
Inclusion Criteria:

* Radius Fractures C1-C2
* age over 70

Exclusion Criteria:

* demetia
* collateral damages
* age \< 70
Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B

The purpose of this study is to learn about experiences of patients with hemophilia A and B after taking gene therapy. The experiences of patients will be studied through online interviews.

This study is seeking participants who are:

* part of the Pfizer's gene therapy clinical studies or
* in the long-term follow up for these clinical programs. Participants will have one study visit at the clinic and one online interview. The planned duration for each participant will be 1 to 2 months. This covers the time from entering the study to end of the online interview.


Eligibility Criteria:
Inclusion Criteria:

* Participation in the Pfizer's gene therapy clinical trials for Hemophilia A or B .
* Participants will be one year or more post-gene therapy
* Participants will be willing to provide written consent and will be willing to comply with the study requirements

Exclusion Criteria:

-No exclusion criteria
Multimodal Analysis of the Young Brain on Rhythm Perception: From Premature Neonates to Infants

Premature neonates are able to discriminate phonemes and voice from 28wGA at a time the neuronal network establish contact between the environment and the cortical neurones. In the present monocentric study the investigators will analyse the response of the cortical network in premature aged between 28 and 40 wGA in response to auditory stimuli using High Resolution Electroencephalography and High Density Near Infrared Spectroscopy


Eligibility Criteria:
Inclusion Criteria:

* Full term neonates between 28 and 40 weeks Gestational Age

Exclusion Criteria:

* Neonates outside the age range
Gastric Ultrasound Prior to Extubation

Serial gastric ultrasound assessments to assess the effect of fasting for 4 hours on gastric volume in mechanically ventilated patients in the ICU fasted for extubation.


Eligibility Criteria:
Inclusion Criteria:

* over 18 years of age,
* mechanically ventilated patients in the ICU,
* intubated with endotracheal
* enteral feeding for over 6 hours before fasting

Exclusion Criteria:

* BMI \> 40, pregnant, fine bore nasogastric tube, mechanical obstruction to gastric emptying, history of upper GI surgeries
Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease

The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with mutations in known heritable thoracic aortic disease (H-TAD) genes, define the phenotype associated with these genes, and determine genetic and environmental modifiers of H-TAD.

The MAC will provide the infrastructure to assemble large cohorts of patients with mutations in known H-TAD genes, define the phenotype associated with these genes, and determine genetic and environmental modifiers and other biomarkers of H-TAD. Recruitment of large numbers of patients world-wide will improve the precision of data used to predict disease risks. Retrospective and prospective study designs will be used to fully characterize the different stages of H-TAD (i.e. susceptibility, presymptomatic, and symptomatic) and other complications associated with the H-TAD genes, and examine clinical and environmental factors that define risk of aortic dissections. The data from MAC will provide the critical clinical information for precise management of thoracic aortic disease and other complications caused by mutations of these genes and improve the medical management and outcome of patients with genetically triggered, lethal vascular diseases.

Eligibility Criteria:
Inclusion Criteria:

* Patients and their relatives with a confirmed pathogenic, likely pathogenic variant, or variant of unknown clinical significance in at least one of the H-TAD genes (i.e. TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, ACTA2, MYH11, MYLK, PRKG1, MAT2A, MFAP5, LOX, COL3A1, FOXE3, and FBN1).
* Patients of all ages, sex and race for which informed consent can be obtained.

Exclusion Criteria:

* Patients without a confirmed causative variant for H-TAD.
The South Texas Aging Registry and Repository

This research registry and repository was designed because the investigators want to learn about how to improve the health and quality of life of older adults.

The South Texas Aging Registry and Repository (STARR) is a database and specimen resource of community dwelling adults from the South Texas area who are interested in volunteering for research studies on aging. The goal is to assist in the inclusion of older adults in clinical research studies and to help to increase the quantity and quality of research relating to them. This registry and repository can be used for various purposes ranging from describing the natural history of aging, identifying risk factors for premature aging, and the real-world effectiveness of life-extending therapies. Collection and storage of biological samples and patient-reported data from of Individuals can help advance research and the development of new awareness of basic mechanisms that play a part in healthy aging or premature death.

Eligibility Criteria:
Inclusion Criteria STARR:

-Age 18 years or older

Inclusion Criteria KAPP Sen TMC:

-Age 20 years and older

Exclusion Criteria STARR:

* Inability to provide informed consent
* Pregnancy

Exclusion Criteria KAPP Sen Tissue Mapping Center (TMC) Study:

* Diabetes
* Hypertension with end-organ damage
* BMI\>30
* GFR\<60 ml/min/1.73 m2
* Cardiovascular disease
* Pancreatitis
* Malignancy other than non-melanoma skin cancers
* Active, uncontrolled pulmonary, hepatic, infectious, gastrointestinal, endocrine, neurologic, or inflammatory disease.
* Chronic use of systemic steroids or use of agents with senolytic activity
* Any disease or condition considered to be exclusionary based on the clinical option and discretion of PI
Microbial Growth in Operative Splash Basins During Total Joint Arthroplasty

The usage of splash basins in the setting of total knee arthroplasty and total hip arthroplasty presents a risk of contamination and subsequent periprosthetic joint infection. Previous studies have investigated the efficacy of multiple antimicrobial irrigants for preventing periprosthetic joint infection, but the results are varied.

Despite several noteworthy studies on the appropriate usage of different antiseptic solutions in surgical splash basins, the current literature has several limitations. First, there are no head-to-head clinical trials comparing betadine and chlorhexidine gluconate (CHG) usage with relation to periprosthetic joint infection and splash basin contamination rates. Second, the in vitro studies directly cultured splash basin antiseptic solutions rather than culturing surgical instruments.

The objective of this study is to compare the microbial contamination rate of total joint arthroplasty instruments that have been placed in surgical splash basins filled with either sterile water, 3.5% betadine, or 0.05% CHG. The overall purpose of the study is to investigate the efficacy of 0.05% CHG and determine if it is an appropriate solution to use in surgical splash basins for joint replacement surgeries.

A prospective clinical trial will be conducted. Patients treated at the Keck Hospital of USC or USC Verdugo Hills Hospital for primary total hip or total knee arthroplasty will be screened for inclusion in our study. All primary surgeries will be performed according to the preferences of the operating surgeon. No deviations from standard surgical care will be made based on inclusion in this study. However, prior to surgery, patients who elect to participate will be randomized to one of three groups: (1) sterile water, (2) 3.5% betadine, or (3) 0.05% CHG.


Eligibility Criteria:
Inclusion Criteria:

* Patients presenting to Keck Hospital of USC or USC Verdugo Hills Hospital for primary total knee arthroplasty or total hip arthroplasty.

Exclusion Criteria:

* Age \< 18 years.
* History of previous total hip arthroplasty or total knee arthroplasty.
* History of previous knee or hip joint infection.
* History of previous allergic reaction to chlorhexidine.
* Known allergy to iodine or shellfish.
Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

This study aims to collect clinical, biological and quality of life data from patients with a borderline or resectable pancreatic cancer. It will collect information from the date of diagnosis along the therapeutic care of the patients, and a 3-years follow-up after the end of the treatment. The database will be updated at each patient's visit. Biological samples will include: tumor, and plasma. Epidemiological data will also be collected, whereas Quality of life will be assessed by the EORTC standard. The objectives of this database are to identify new biomarkers (genomic, immunologic, and epidemiologic) and promote high quality standard research protocol.


Eligibility Criteria:
Inclusion Criteria:

* Patients with exocrine resectable pancreatic adenocarcinoma or potentially resectable (that after neoadjuvant treatment are considered appropriate candidates for resection)
* Histologically or cytologically documented diagnosis of exocrine pancreatic adenocarcinoma
* Written informed consent obtained prior enrollment in the study

Exclusion Criteria:

* other types of pancreatic cancer, in particular endocrine tumor or acinar cells
* ampulloma
* metastatic disease
* other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer
* patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study
* patient under guardianship, curator or under the protection of justice.
Outpatient Floor Pedal Bike Utilization

The goals of this clinical trial are: to test the feasibility of identifying patients and getting patients the floor pedal bikes, to test how well floor pedal bikes help patients with lower body injuries heal, and to test methods of patient self-reported logs for home pedal bike use.

Participants will be given a floor pedal bike at first post-operative appointment where weightbearing restrictions are lifted (weight-bearing as tolerated) along with instructions on utilization. Participants will be asked to complete patient reported outcome measure surveys at each follow-up visit.

The goals of this clinical trial are:

1. to test the feasibility of identifying patients and getting patients the floor pedal bikes themselves
2. to test the efficacy of floor pedal bikes in the rehabilitation of patients with lower extremity orthopedic trauma injuries without formal physical therapy or as a supplement to preexisting and/or future physical therapy. We hope that these bikes will either supplement patient's preexisting therapy or allow them to complete therapy at home if they are unable to obtain formal physical therapy and
3. to test various methods of patient self-reported logs for home pedal bike utilization, whether electronic or hard paper copy.

Participants will be given a floor pedal bike at first post-operative appointment where weightbearing restrictions are lifted (weight-bearing as tolerated) along with instructions on utilization. Participants will be asked to complete patient reported outcome measure surveys at each follow-up visit.

Eligibility Criteria:
Inclusion Criteria:

* Patients \>18 years of age
* Operative fractures of the femur, tibia and select ankle injuries
* Under the care of an orthopaedic surgeon
* English or Spanish competent
* 12 month follow up

Exclusion Criteria:

* Type IIIB/C fracture
* Unable to provide consent/need for an LAR
* Major lower extremity peripheral nerve injury (ex. foot drop, sciatic nerve palsy, etc)